Syros Pharmaceuticals, Inc. Common Stock
SYRS
SYRS was delisted on the 19th of March, 2025.
68 hedge funds and large institutions have $321M invested in Syros Pharmaceuticals, Inc. Common Stock in 2019 Q2 according to their latest regulatory filings, with 14 funds opening new positions, 35 increasing their positions, 14 reducing their positions, and 9 closing their positions.
30,933% more call options, than puts
Call options by funds: $931K | Put options by funds: $3K
150% more repeat investments, than reductions
Existing positions increased: 35 | Existing positions reduced: 14
56% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 9
48% more capital invested
Capital invested by funds: $218M → $321M (+$104M)
5% more funds holding
Funds holding: 65 → 68 (+3)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NAMA
Nikko Asset Management Americas
New York
|
+$16M |
| 2 |
RG
Redmile Group
San Francisco,
California
|
+$13.8M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$7.56M |
| 4 |
Sumitomo Mitsui Trust Group
Minato-Ku, Tokyo,
Japan
|
+$6.3M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$6.01M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WCM
Wedge Capital Management
Charlotte,
North Carolina
|
-$762K |
| 2 |
AA
ALPS Advisors
Denver,
Colorado
|
-$743K |
| 3 |
Millennium Management
New York
|
-$637K |
| 4 |
Connor, Clark & Lunn Investment Management (CC&L)
Vancouver,
British Columbia, Canada
|
-$627K |
| 5 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$315K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
MAM
76
Meeder Asset Management
Dublin,
Ohio
| – | -$3K | -28 | Closed |
|
77
Group One Trading
Chicago,
Illinois
| – | +$209 | +3 | New |
|
SYRS Hedge Fund Activity: Q2 2019 in Review
68 of the 4,605 institutional investors tracked by Wall St. Rank reported a position in Syros Pharmaceuticals, Inc. Common Stock (SYRS) for Q2 2019, worth a combined $321M — up 48% from $218M a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new SYRS positions and 9 closed out — a net gain of 5 holders — while 35 added to existing stakes and 14 trimmed.
The largest buyer was Nikko Asset Management Americas, adding an estimated $16M. The largest seller was Wedge Capital Management, exiting entirely with an estimated $762K sold.
- 68 institutional investors held Syros Pharmaceuticals, Inc. Common Stock (SYRS) as of Q2 2019, up from 65 in Q1 2019.
- Funds reported $321M of Syros Pharmaceuticals, Inc. Common Stock stock for Q2 2019, up 48% quarter-over-quarter.
- 14 funds opened new Syros Pharmaceuticals, Inc. Common Stock positions in Q2 2019 and 9 closed out, a net change of +5 holders.
- The largest Syros Pharmaceuticals, Inc. Common Stock buyer in Q2 2019 was Nikko Asset Management Americas, an estimated $16M added.
- The largest Syros Pharmaceuticals, Inc. Common Stock seller in Q2 2019 was Wedge Capital Management, an estimated $762K sold.
Based on aggregated 13F filings for Q2 2019.